387 results about "Prostate" patented technology

A dietary supplement composition is formulated in a therapeutic amount to maintain and promote urinary and prostate function in a human. The composition includes a shelf stable, supercritical CO2 fluid extracted, enhanced lipidosterolic extract of Serenoa repens (LSESr). The enhanced LSESr has a ratio of free fatty acids to total fatty acids that is greater than about 83.0% and an enrichment of lauric, myristic, oleic and linoleic acids as free fatty acids to total free fatty acids that is about 81.0% or greater.

A cross-modal cross-dimension prostate nuclear magnetic ultrasound image registration method belongs to the technical field of medical image processing and artificial intelligence auxiliary diagnosis and treatment, and comprises the following steps: firstly, equivalently reconstructing a registration task into two sub-tasks; providing a cross-modal double-branch attention mechanism to realize semantic alignment according to modal differences; and aiming at the dimension difference, designing a lightweight rigid positioning network to carry out affine slice transformation. According to the method, through equivalent problem reconstruction, the modeling difficulty and the calculation complexity are remarkably reduced; a dual-module structure combining elastic and rigid registration is designed, and the registration precision and clinical adaptability are comprehensively improved; a cross-modal double-branch attention mechanism is introduced, and the overall transformation effect is optimized while the precision of the local anatomical structure is kept; a three-stage combined training strategy is adopted, the three-stage combined training strategy comprises contrast learning pre-training, module-level training and whole-network fine tuning, optimization is carried out in combination with weak supervision signals (segmentation labels), a high-quality registration result can be obtained under the condition of no registration labels or a small number of labels, and data dependence and training cost are reduced.

The invention belongs to the technical field of medical image digital image processing, and particularly relates to a prostate TRUS-MRI registration method based on multi-scale weighting and an adaptive window, and the method comprises the steps: firstly collecting an ultrasonic image and a magnetic resonance image of a prostate, dividing the ultrasonic image and the magnetic resonance image into a training set, a verification set and a test set, and sketching a mask for a prostate gland in each image; then the input image is preprocessed; then, UNet is adopted as a feature extractor, a deformation field is output in combination with a spatial transformation network, deformation is applied through an STN pair, and a registration image is obtained; the method comprises the following steps: firstly, acquiring three parts of an ultrasonic image, then constructing a network loss function, finally, acquiring a total loss function according to the three parts of the network loss function, performing staged training, finally, outputting the total network loss function, processing a subsequent ultrasonic image and a magnetic resonance image, and outputting a registration image. Compared with the prior art, the method has the comprehensive advantages of cross-modal adaptability, detail optimization capability, calculation efficiency and generalization performance, so that the method is remarkably improved.

The present invention relates to an endoscopic probe for photoacoustic tomography of cavity side walls, characterized by comprising a hollow tubular probe housing with a closed front end; N acoustic wave receiving windows and M laser output windows formed on the side wall of the tubular probe housing; an array of linear laser output ports connected to a pluggable optical fiber connector via an optical fiber bundle; and an ultrasonic transducer array connected to a multi-channel signal connector via a signal harness. The present invention employs a method of arranging array transducers and array laser outputs on the side wall of the probe, eliminating the need for a reflector. The probe is less than 2 centimeters in size and can be placed in close proximity to the prostate through the rectum for photoacoustic imaging of the prostate, or in close proximity to the inner wall of the rectum for photoacoustic imaging of the inner wall of the rectum. The endoscopic probe provided by the present invention, combined with a photoacoustic imaging system host, utilizes photoacoustic endoscopic imaging technology to perform real-time transrectal prostate imaging and rectal imaging, achieving ideal imaging results.

The present disclosure relates to a method of treating prostate specific membrane antigen (PSMA) positive progressive metastatic castration resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA binding radioligand therapy (RLT) agent, preferably [177Lu] Lu-PSMA-617 (lutetium (177Lu) vevovortitide Tailaracetam), to a taxane primarily treated patient whose disease progresses after receiving a second generation ARPI.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-4, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-4. The invention also provides application of the keratin YK93-4 and related products thereof in preparation of medicines for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, benign prostatic hyperplasia and the like.

The invention belongs to the technical field of medical image processing, and particularly relates to a prostate MRI-TRUS deformable image registration method based on structure perception decoupling learning. The method comprises the following steps: designing an anatomical maintenance intensity disturbance module, simulating intensity and artifact differences between different modes on the premise of keeping an anatomical structure unchanged, and generating diversified appearance samples to improve the adaptability of the model to mode changes; a double-flow encoder structure is constructed, space attention latent consistency loss is introduced into a multi-layer feature space, the structure consistency is restrained from the feature level, and deep structure representation learning with the unchanged appearance is achieved; and an enhanced pyramid decoder is adopted to fuse multi-scale structural features layer by layer to predict a registration deformation field, so that high-precision cross-modal alignment is realized. According to the method, structural consistency constraint is carried out on the hidden space level, so that the influence of modal difference and artifacts can be effectively reduced, and the registration precision is improved.

The present disclosure relates to pharmaceutical compositions comprising [61Cu]Cu-NODAGA-PSMA I&T or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of imaging subjects suspected of having or diagnosed with a prostate-specific membrane antigen (PSMA)-expressing tumor by administering the pharmaceutical compositions described herein and generating one or more radiographic images of the subject.

The present disclosure relates to the synthesis of prostate-specific membrane antigen (PSMA) ligands useful in the treatment of diseases such as cancer. In particular, the present disclosure relates to methods for synthesizing PSMA ligands having a glutamic acid-urea-lysine (GUL) moiety and a chelator that may include a radiometal.

The invention relates to a molecular probe for targeting a prostate specific membrane antigen and application, and belongs to the technical field of nuclear medicine. The invention provides a molecular probe for targeting a prostate specific membrane antigen, and the molecular probe successfully obtains a PSMA targeting molecular probe by introducing iodobenzene butyric acid and a PEG4 group on the basis of a PSMA-617 molecular structure on the basis of a double-ligand covalent coupling technology. The molecular probe has the advantages that the residence time of the molecular probe in a tumor area is obviously prolonged, the treatment effect is improved, the requirement for radioactive dose is reduced, and radiation damage to surrounding normal tissues is reduced; the specificity is excellent, a tumor area with high PSMA expression can be accurately targeted, and tumors with different PSMA expression levels can be effectively distinguished; the speed of reaching a target tumor is high, and an ideal imaging effect can be realized only in 20 minutes. In conclusion, the molecular probe has great advantages in diagnosis and treatment of PSMA high-expression tumors, and has high specificity and high efficiency.

The invention belongs to the technical field of medical image segmentation, and relates to a dual-path fusion neural network for prostate precise segmentation and a segmentation method, the neural network constructs a dual-path decoupling encoder architecture based on an nnU-Net framework, captures fine anatomical structure and local texture information through a context sensing residual encoder of a local path, and obtains a dual-path fusion neural network for prostate precise segmentation. A long-range dependency relationship is modeled with linear complexity through a visual state space module of a global path, a double-flow alignment gating module is designed to realize self-adaptive alignment and fusion of cross-path features, and model training is optimized in combination with a mixed loss function and a depth supervision strategy; according to the method, the limitation of an existing segmentation model in the aspect of local structure and global semantic integration is solved, and the segmentation precision, the boundary goodness of fit and the generalization performance of the focus and gland region in the prostate MRI image are improved.

The invention discloses a prostate MRI image segmentation method and system based on an improved U-Net network, and a storage medium, and relates to the technical field of medical image processing. The invention discloses a prostate MRI image segmentation method based on an improved U-Net network. The method comprises the steps of obtaining a prostate MRI image data set, performing slicing processing on each piece of 3D image data in the prostate MRI image data set, and setting a pixel effective area to obtain a prostate input image; a basic U-Net network model is constructed and improved, an up-sampling module symmetrical to down-sampling is added in an encoder, a new down-sampling module is added after the added up-sampling, and a double-branch structure of first down-sampling and then up-sampling and first up-sampling and then down-sampling is formed; meanwhile, an efficient additive attention module is added between the encoder module and the decoder module, so that an O-Net network model is obtained; the prostate input image is input into the O-Net network model, a prostate MRI image segmentation result is obtained, and the segmentation precision of edge details is remarkably improved while deep semantic information is kept.

The invention discloses a prostate precise puncture robot path planning method based on deep learning, and relates to the field of path planning, and the method comprises the steps: carrying out the global path planning based on MRI data before an operation, and abstracting a puncture environment and a planned path into a graph structure model; in an operation, dynamic deformation of the prostate is perceived through a real-time ultrasonic image, and an affected local dangerous area in an initial path diagram is accurately identified based on deformation information. And then, a graph neural network technology is introduced, rapid and intelligent rerouting calculation is performed on the affected local sub-graph to generate a new safe local path, and finally, the new path is seamlessly integrated into the original global path graph to complete efficient correction of the overall path. Therefore, the time-consuming bottleneck of global calculation can be avoided, so that the real-time problem of dynamic path correction in an operation is solved on the premise of ensuring high precision, and the path planning capability of the robot in a dynamic environment is remarkably improved.

The invention belongs to the field of biological pharmacy, and provides keratin YK93-5, a coding nucleic acid molecule thereof, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or genome integrated with the nucleic acid molecule, and a preparation method and a pharmaceutical composition of the keratin YK93-5. The invention also provides application of the keratin YK93-5 and other products in preparation of drugs for treating lung cancer, lymphoma, breast cancer, melanoma, hysteromyoma, prostatic hyperplasia and the like.

Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer are disclosed.

The invention discloses a prostate MR image segmentation method and system based on multi-level context aggregation, and the method comprises the steps: segmenting a prostate MR image through a trained prostate MR image segmentation model, and obtaining a segmentation result. The model is based on an improved U-shaped architecture and comprises a multi-level coding module, a jump connection processing module, a bottleneck layer, a multi-level decoding module and a segmentation head. The multi-level coding module extracts image features of different levels, and the jump connection processing module generates enhanced features through combination of hierarchical expansion convolution and an improved Transform architecture; the bottleneck layer decouples the bottom layer features into foreground / background features, and outputs a feature map through local window attention weighted fusion; and the multi-level decoding module gradually recovers the resolution through residual convolution and bilinear up-sampling, and finally outputs a binary segmentation result through a segmentation head. According to the method, the accuracy and robustness of prostate MR image segmentation are improved through hierarchical feature aggregation and attention fusion.

Provided herein are prostate specific membrane antigen (PSMA) antibodies, e.g., human monoclonal antibodies against PSMA, nucleic acid molecules encoding the antibodies, expression vectors and host cells for expressing the antibodies, methods for making the same, and uses thereof, e.g., in the treatment of PSMA-related diseases, including cancer.

The present invention discloses an antibody targeting prostate-specific membrane antigen, an antigen-binding fragment thereof, a preparation method and uses thereof. In the antibody or its antigen-binding fragment, the amino acid sequences of HCDR1, HCDR2 and HCDR3 are respectively as shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; and / or, the amino acid sequences of LCDR1, LCDR2 and LCDR3 are respectively as shown in SEQ ID NO:7, SEQ ID NO:8 and SEQ ID NO:9. The antibody can specifically bind to the extracellular domain protein of human and monkey PSMA, can effectively bind to C4-2 and 22RV1 cells, and the ADC containing the same can effectively kill tumor cell lines.

The invention discloses a prostate segmentation method fusing multi-scale attention, and relates to the technical field of medical image processing, and the key points of the technical scheme are that a feature extraction unit in the method is composed of three parts of convolution-attention-convolution: initial convolution is used for extracting input high-order features; then, an introduced attention module extracts multi-level context information through a plurality of convolutional networks with different scales, and redundant features are screened in combination with a gating mechanism, so that key information is reserved; and the final layer of convolution performs fine adjustment on the fused features. In order to further improve the fusion effect, a feature reconstruction strategy based on a self-attention mechanism is also introduced in the scheme, so that the model can fully understand and integrate multi-scale information, and the robustness of the model is improved while the segmentation precision is ensured.

The present disclosure relates to novel deuterated retinoidal compounds and methods of preparing the deuterated retinoidal compounds. The present disclosure also provides pharmaceutical compositions including the deuterated retinoidal compounds, and uses of the deuterated retinoidal compounds to treat diseases including breast and prostate cancers.

Disclosed are a prostate puncture guidance method, apparatus, device and system based on multi-modal fusion. The prostate model of the object to be examined and the ultrasonic probe model with at least one scanning plane are displayed in the same display area. Based on the real-time coordinate and ultrasound image information collected by the ultrasonic probe, the display area dynamically displays dynamic updates. Users may get the positional relationship between at least one scanning plane and the target identifier in the prostate model. This allows for quickly and accurately understanding the intersection between the scanning plane corresponding to the puncture plate installed on the ultrasonic probe and the target identifier. Additionally, through another display area showing the correlation between the specific puncture hole in the puncture plate and the target identifier, sampling can be quickly completed through the sampling device by penetrating the specific puncture hole.

The invention discloses a classification method and a classification device for prostate significant cancer. The classification method comprises the following steps: acquiring a plurality of magnetic resonance images, and selecting a T2 sequence and a plurality of diffusion weighted image DWI sequences with different b values from the magnetic resonance images; processing the plurality of DWI sequences to obtain at least one apparent diffusion coefficient ADC sequence; extracting one sequence from the T2 sequence, the plurality of DWI sequences and the at least one ADC sequence as a basic segmentation sequence, and segmenting each image in the basic segmentation sequence by using a pre-trained deep learning model to segment prostate glands and prostate lesions; based on the segmented basic segmentation sequence, segmenting each image in other sequences; training a classification model by using all the segmented sequences to obtain a trained classification model; and inputting magnetic resonance imaging to be classified into the trained classification model for classification. The method can be used for accurately and efficiently detecting the prostate remarkable cancer.

The invention discloses a tiny focus recognition method for prostate puncture and application, and the method comprises the steps: S1, collecting and preprocessing an MRI image and an ultrasonic image of a patient, and obtaining a preprocessed MRI image and a preprocessed ultrasonic image; s2, constructing a texture attention residual network, and extracting MRI texture enhancement features; constructing a multi-scale edge response gating network, and extracting ultrasonic edge enhancement features; s3, performing spatial transformation and resampling on the ultrasonic edge enhancement features to obtain aligned ultrasonic enhancement features; s4, calculating a focus area weight feature matrix, an MRI dynamic weight matrix, an ultrasonic dynamic weight matrix, redundancy-removed MRI features, redundancy-removed ultrasonic features and tiny protection features; and S5, identifying the tiny focus area, and controlling the puncture robot to puncture. The problems that a traditional method is poor in tiny focus recognition capacity, missed diagnosis of the focus is prone to occurring, and puncture accuracy is insufficient can be solved.

A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is —R1aR1b— wherein R1a is absent, —CH2—, —O—, or —S—, and R1b is —CH2— or —CHF—. R2 is —(CH2)3—O—, —(CH2)3—, —(CH2)4—, —CH2—O—(CH2)2—, or —CH2—S—(CH2)2. R3 is ethylene fused to a tricyclic fused ring. L1, L2, L3, L4, L5b L5c, L6 and L7 are linkages (e.g. peptide bonds). Xbr is a branching atom. Rrad is a radiometal chelator. Ralb is an albumin binder. n1, n2, n3, n4, and n5 are integers. When the PSMA-targeting moiety is linked to a radiolabeling group, the compound may be used as an imaging agent or therapeutic agent for PSMA-expressing diseases / conditions.

A transperineal biopsy guide for use with an access needle and a transrectal imaging probe. The transperineal biopsy guide includes a mount, a guide member, and an access needle support structure. The mount is attachable to the probe. The guide member includes: a first side comprising a first distal member and a first surface extending proximally from the first distal member; a second side comprising a second distal member and a second surface extending proximally from the second distal member; and a gap between the first distal member and the second distal member. The access needle support structure is securable to the guide member in a distal position that inhibits vertical and distal displacement of the access needle support structure relative to the guide member while permitting disengagement from the distal position via proximal movement of the access needle support structure relative to the guide member.

A prostate-specific membrane antigen (PSMA)-targeting conjugate having a phosphonate backbone, which is used for tumor detection after chelation of a diagnostic nuclide and is used for radiation therapy after being combined with a treatment-type nuclide. A conjugate nuclide chelation part is replaced with a fluorescent probe or a cytotoxic drug so that the PSMA-targeting conjugate can then be used for diagnosis and treatment of diseases.

The present invention relates to adenosine derivatives for use in cancer therapies, and particularly although not exclusively, to hormone-dependent cancer therapies, for example methods for treating, preventing or ameliorating prostate or breast cancer. Additionally, the present invention relates to methods for treating, preventing or ameliorating pancreatic cancer. The invention also extends to esters of Aspartyl-adenylate and to their use in therapy.

To provide a prostate treatment system capable of applying condensable vapor energy to tissue such as the prostate to shrink, damage, and denature the prostate.SOLUTION: A prostate treatment system includes an introducer shaft, a vapor generator configured to generate a condensable vapor, a vapor delivery needle in communication with the vapor generator and movably disposed within the introducer shaft, a wire configured to provide an electrical current to move the vapor delivery needle, a sensor configured to measure a characteristic of the electrical current flowing through at least a portion of the wire, and a controller configured to determine a state of the vapor delivery needle based on data from the sensor.SELECTED DRAWING: Figure 1C

Methods and compositions for treatment of prostate cancers, such as androgen receptor (AR) deficient and androgen receptor (AR) low cancers, are disclosed. The methods include administration of an agent that inhibits activity of eIF4F or an agent that disrupts the eIF4F translation-initiation complex (composed of eIF4E, eIF4A, and eIF4G).

1. The name of the design product: red light therapeutic instrument (prostate). 2. The use of the design product: for red light therapy. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.